<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703998</url>
  </required_header>
  <id_info>
    <org_study_id>5702</org_study_id>
    <nct_id>NCT04703998</nct_id>
  </id_info>
  <brief_title>Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma</brief_title>
  <official_title>Arthroscopic Rotator Cuff Repair Augmented With Platelet Rich Plasma. Prospective Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To assess whether the use of platelet-rich plasma used as an adjuvant to&#xD;
      arthroscopic rotator cuff repairs modify the rate of re-tears (measured by MRI) compared to a&#xD;
      control group that only underwent the isolated arthroscopic repair. Hypothesis: Platelet rich&#xD;
      plasma used as an adjuvant to arthroscopic rotator cuff repairs decrease the rate of retears.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of re-tear rates between groups.</measure>
    <time_frame>6 months</time_frame>
    <description>Postoperative MRI to assess the structural integrity of the repaired rotator cuff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From baseline in shoulder functional scores at 3, 6 and 12 months</measure>
    <time_frame>baseline, 3, 6, and 12 months</time_frame>
    <description>The ASES score (American Shoulder and Elbow Surgeons) and the Constant score will be used. Both scores assess the general function of the shoulder in different activities of daily life, global mobility of the shoulder and pain with usual tasks. They are scores ranging from 0 to 100. Both scores are validated and are the reference scores for clinical research on rotator cuff pathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From baseline in pain at 3, 6 and 12 months</measure>
    <time_frame>baseline, 3, 6, and 12 months</time_frame>
    <description>The visual analog scale (VAS) will be used to assess the level of pain during activities of daily living. 0 will be considered as &quot;no pain&quot; and 10 as &quot;the worst pain of his life.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Adverse effects and postoperative complications will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rotator Cuff Tears</condition>
  <arm_group>
    <arm_group_label>Arthroscopic rotator cuff repair and platelet rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard double-row arthroscopic rotator cuff repair will be performed and at the end of the procedure 10 ml of autologous platelet-rich plasma will be placed under direct vision at the tendon-bone interface.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arthroscopic rotator cuff repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A standard double-row arthroscopic rotator cuff repair will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroscopic rotator cuff repair</intervention_name>
    <description>A double-row rotator cuff repair will be performed.</description>
    <arm_group_label>Arthroscopic rotator cuff repair</arm_group_label>
    <arm_group_label>Arthroscopic rotator cuff repair and platelet rich plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet rich plasma</intervention_name>
    <description>A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.</description>
    <arm_group_label>Arthroscopic rotator cuff repair and platelet rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 50 and 75 years with a defined complete rotator cuff tear as compatible&#xD;
             clinical and confirmation by magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  Minimum of 3 months of failed conservative treatment (anti-inflammatory, physical&#xD;
             therapy and infiltration with corticosteroids)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate or informed consent,&#xD;
&#xD;
          -  Revision surgery,&#xD;
&#xD;
          -  Partial repair,&#xD;
&#xD;
          -  Patients with shoulder osteoarthritis&gt; 2&#xD;
&#xD;
          -  Advanced fat infiltration of the rotator cuff muscles (STAGE 3 or 4)&#xD;
&#xD;
          -  Systemic or rheumatoid arthritis,&#xD;
&#xD;
          -  Uncontrolled diabetes, (patients for whom surgery is contraindicated in the&#xD;
             preoperative evaluation by the clinician and anesthesiologist)&#xD;
&#xD;
          -  Acute or chronic infections of the shoulder to be operated on&#xD;
&#xD;
          -  Ongoing cancer chemotherapy therapies&#xD;
&#xD;
          -  Sepsis, septic arthritis, osteomyelitis or other ongoing infectious processes;&#xD;
&#xD;
          -  Previous operations on the affected shoulder,&#xD;
&#xD;
          -  Patients with autoimmune diseases;&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciano Rossi, MD</last_name>
    <phone>+54 9 1158733374</phone>
    <email>luciano.rossi@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ignacio pasqualini, MD</last_name>
    <phone>+54 9 1159624641</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Rossi, MD</last_name>
      <phone>49529500</phone>
      <email>luciano.rossi@hospitalitaliano.org.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>LUCIANO ANDRES ROSSI</investigator_full_name>
    <investigator_title>Pincipal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

